Listing of Pharmaceutical Public Law Correspondence
Correspondence |
File Size |
Dear Manufacturer of Covered Drugs 10/2007
|
62 kb |
Dear Manufacturer of Covered Drugs 10/2006
|
62 kb |
Dear Manufacturer FAMP Concerns 10/2004
|
77.1 kb |
Dear Manufacturer of Covered Drugs letter 10/2004 |
33 kb |
Dear Manufacturer of Covered Drugs 07/2004
|
32.1 kb |
Office of General Counsel Letter 03/2004
regarding calculation of FCPs for Flu Vaccines |
160 kb |
Public Law Correspondence Index |
96 kb |
Annual Guidance 10/2002
|
49 kb |
Dear Manufacturer Letter 10/2001
regarding who is a manufacturer under a licensing
agreement, determination regarding certain purchases by INS, exclusion
of sales to § 602 entities at less than the statutory price through
their PPV's, and calculation of new covered drug pricing |
171 kb |
Annual Guidance 10/2001
|
198 kb |
Annual Guidance 10/2000
|
205 kb |
Annual Guidance 10/1999
|
481 kb |
Dear Manufacturer Cover Letter 10/1999
regarding all previous correspondence |
83 kb |
Annual Guidance 10/1998
|
533 kb |
Office of General Counsel Letter 05/1998
regarding calculation of FCPs for Flu Vaccines |
99 kb |
Response to Pharmacia Letter 11/1997
|
131 kb |
Letter from Pharmacia and Upjohn 10/1997
regarding private label packaging |
131 kb |
Annual Guidance 10/1997
|
178 kb |
Dear Manufacturer Letter 10/1997
regarding record retention, 2-step computation, transferring covered drugs from one manufacturer to another, and custom or private label packaging |
198 kb |
Dear Manufacturer Letter 02/1997
regarding penny prices for single schedule companies |
93 kb |
Annual Guidance 10/1996
|
178 kb |
Supplementary Guidance 10/1996
regarding nominal prices, drug samples and TRICARE |
149 kb |
Annual Guidance 09/1995
|
159 kb |
Dear Manufacturer Letter 09/1995
conveying common errors observed by the Office of the Inspector General in the computation of the FCPs |
169 kb |
Annual Guidance 09/1994
|
192 kb |
Dear I.V. Solutions Manufacturer Letter 10/1993
regarding covered drug status of certain I.V. Solutions |
52 kb |
Annual Guidance 10/1993
|
210 kb |
Addition of New Covered Drugs 09/1993
|
139 kb |
Office of General Counsel Letter 07/1993
regarding delegation of Hearing Responsibility, Title VI, P.L. 102-585, Drug Pricing Agreement |
128 kb |
Dear Manufacturer Letter 06/1993
regarding sales from "any State or Territory of the United States, the District of Columbia, and the Commonwealth of Puerto Rico" |
57 kb |
Office of General Counsel Letter 05/1993
Dear Manufacturer Letter 10/1997
regarding transfer of covered drugs |
79 kb |
Dear Manufacturer Letter 05/1993
regarding technical amendment to the P.L.
(dual pricing) |
234 kb |
Dear
Member of the I.V. Solutions Industry Letter 04/1993
regarding the
covered status of I.V. Solutions |
93 kb |
Dear
Radiopharmaceutical Industry Member Letter 04/1993
regarding agreement
between the Department
and the manufacturer that Radiopharmacies
will not be
considered wholesalers |
80 kb |
Assistant General Counsel Letter 03/1993
to the Deputy Assistant Secretary for
Acquisition and Materiel Management regarding Impact of Public Law
102-585 on
FSS Contract Pricing |
200 kb |
Dear Manufacturer Letter 02/1993
regarding request for increase to the FCP |
137 kb |
Dear Radiopharmacy Operator Letter 02/1993
regarding whether Radiopharmacies
need to enter into Master Agreements |
80 kb |
Dear Manufacturer Letter 12/1992
regarding request for increase to the FCP |
88 kb |
Annual Guidance 11/1992
|
85 kb |
Correspondence Archive
|
4866 kb |